Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy.

Kelderman S, Heemskerk B, Fanchi L, Philips D, Toebes M, Kvistborg P, van Buuren MM, van Rooij N, Michels S, Germeroth L, Haanen JB, Schumacher NM.

Eur J Immunol. 2016 Jun;46(6):1351-60. doi: 10.1002/eji.201545849. Epub 2016 May 3.

3.

Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy.

Benlalam H, Labarrière N, Linard B, Derré L, Diez E, Pandolfino MC, Bonneville M, Jotereau F.

Eur J Immunol. 2001 Jul;31(7):2007-15.

4.

Dissection of T-cell antigen specificity in human melanoma.

Andersen RS, Thrue CA, Junker N, Lyngaa R, Donia M, Ellebæk E, Svane IM, Schumacher TN, Thor Straten P, Hadrup SR.

Cancer Res. 2012 Apr 1;72(7):1642-50. doi: 10.1158/0008-5472.CAN-11-2614. Epub 2012 Feb 6.

5.

TIL 2.0: More effective and predictive T-cell products by enrichment for defined antigen specificities.

Schober K, Busch DH.

Eur J Immunol. 2016 Jun;46(6):1335-9. doi: 10.1002/eji.201646436.

6.

Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors.

Hall M, Liu H, Malafa M, Centeno B, Hodul PJ, Pimiento J, Pilon-Thomas S, Sarnaik AA.

J Immunother Cancer. 2016 Oct 18;4:61. doi: 10.1186/s40425-016-0164-7. eCollection 2016.

7.

Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.

Prieto PA, Durflinger KH, Wunderlich JR, Rosenberg SA, Dudley ME.

J Immunother. 2010 Jun;33(5):547-56. doi: 10.1097/CJI.0b013e3181d367bd.

8.

Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.

Kawakami Y, Dang N, Wang X, Tupesis J, Robbins PF, Wang RF, Wunderlich JR, Yannelli JR, Rosenberg SA.

J Immunother. 2000 Jan;23(1):17-27.

PMID:
10687134
9.

Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.

Moore TV, Lyons GE, Brasic N, Roszkowski JJ, Voelkl S, Mackensen A, Kast WM, Le Poole IC, Nishimura MI.

Cancer Immunol Immunother. 2009 May;58(5):719-28. doi: 10.1007/s00262-008-0594-2. Epub 2008 Oct 3.

10.

Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.

Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, Hwu P, Radvanyi LG.

J Immunother. 2011 Apr;34(3):236-50. doi: 10.1097/CJI.0b013e318209e7ec.

11.

Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ, Hwu P, Radvanyi LG.

Cancer J. 2012 Mar-Apr;18(2):160-75. doi: 10.1097/PPO.0b013e31824d4465. Review.

12.

Effector T cell analysis of melanoma tumor-infiltrating lymphocyte cultures using HLA-ABC semimatched melanoma cell lines.

Carlsson B, Sadeghi A, Bengtsson M, Wagenius G, Tötterman TH.

J Immunother. 2008 Sep;31(7):633-43. doi: 10.1097/CJI.0b013e3181822097.

PMID:
18600181
13.

Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis.

Shitaoka K, Hamana H, Kishi H, Hayakawa Y, Kobayashi E, Sukegawa K, Piao X, Lyu F, Nagata T, Sugiyama D, Nishikawa H, Tanemura A, Katayama I, Murahashi M, Takamatsu Y, Tani K, Ozawa T, Muraguchi A.

Cancer Immunol Res. 2018 Apr;6(4):378-388. doi: 10.1158/2326-6066.CIR-17-0489. Epub 2018 Feb 23.

14.

Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy.

Godet Y, Desfrançois J, Vignard V, Schadendorf D, Khammari A, Dreno B, Jotereau F, Labarrière N.

Eur J Immunol. 2010 Jun;40(6):1786-94. doi: 10.1002/eji.200940132.

15.

Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide.

Salgaller ML, Weber JS, Koenig S, Yannelli JR, Rosenberg SA.

Cancer Immunol Immunother. 1994 Aug;39(2):105-16.

PMID:
7519125
16.

TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.

Liu S, Etto T, Rodríguez-Cruz T, Li Y, Wu C, Fulbright OJ, Hwu P, Radvanyi L, Lizée G.

J Immunother. 2010 May;33(4):371-81. doi: 10.1097/CJI.0b013e3181cd1180.

PMID:
20386469
17.

T cell-defined melanoma antigens: toward a tumour-specific immunotherapy of the disease.

Parmiani G.

Melanoma Res. 1993 Dec;3(6):391-3. No abstract available.

PMID:
7909243
18.

Identification of Melanoma-reactive CD4+ T-Cell Subsets From Human Melanoma Draining Lymph Nodes.

Zhang M, Graor H, Yan L, Kim J.

J Immunother. 2016 Jan;39(1):15-26. doi: 10.1097/CJI.0000000000000103.

19.

T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.

Tjin EP, Konijnenberg D, Krebbers G, Mallo H, Drijfhout JW, Franken KL, van der Horst CM, Bos JD, Nieweg OE, Kroon BB, Haanen JB, Melief CJ, Vyth-Dreese FA, Luiten RM.

Clin Cancer Res. 2011 Sep 1;17(17):5736-47. doi: 10.1158/1078-0432.CCR-11-0230. Epub 2011 Jul 12.

20.

Lymphocyte-melanoma interaction: role of surface molecules.

Becker JC, Bröcker EB.

Recent Results Cancer Res. 1995;139:205-14. Review.

PMID:
7597291

Supplemental Content

Support Center